Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy [Seeking Alpha]
Roivant Sciences Ltd. - Common Shares (ROIV)
Company Research
Source: Seeking Alpha
Brepocitinib is clearly now becoming a broader immunology franchise across DM, NIU, CS, and LPP. ROIV also settled with Moderna regarding LNP, which adds to its already cash-rich balance sheet and supports its ongoing buybacks and pipeline. However, ROIV's valuation is at a premium, which has reduced its margin of safety and highlights the remaining execution risks going forward. Despite these caveats, ROIV remains attractive for patient, long-term investors who are betting on management pivoting from seeking M&A deals to growing revenues. Solskin/DigitalVision via Getty Images Roivant Sciences Ltd. ( ROIV ) is a late-stage biotechnology company that operates through subsidiaries called Vants. Its current pipeline is centered on immunology and specialty diseases. ROIV also has brepocitinib, a TYK2/JAK1 inhibitor being developed by Priovant for
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (ROIV) was given a new $40.00 price target by Piper Sandler.MarketBeat
- Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]Yahoo! Finance
- Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]USA TODAY
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/22/26 - Form 4
- 4/22/26 - Form 4
- 4/22/26 - Form 4
- ROIV's page on the SEC website